Showing results (151-160 of 319) with videos related to

Sort By:
Pageof 32
International Journal of Hematology|August 8, 2019
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. TrialsMeletios A Dimopoulos, Philippe Moreau, Shinsuke Iida, et al.
British Journal of Pharmacology|April 22, 2011
Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cellsRadhamani Kannaiyan, Hui Sin Hay, Peramaiyan Rajendran, et al.
Leukemia & Lymphoma|September 23, 2017
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR studyHartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, et al.
Leukemia Research|July 3, 2013
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma networkDaryl Tan, Kihyun Kim, Jin Seok Kim, et al.
Haematologica|January 5, 2019
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinationsSu Lin Lim, Alisa Damnernsawad, Pavithra Shyamsunder, et al.
Investigational New Drugs|June 19, 2015
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 doseKarthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, et al.
JCI Insight|May 4, 2018
Universal monitoring of minimal residual disease in acute myeloid leukemiaElaine Coustan-Smith, Guangchun Song, Sheila Shurtleff, et al.
Cancer Reports (Hoboken, N.J.)|December 23, 2025
Incidence and Clinical Outcomes of Vitamin D Status and Myeloma Bone Disease Among Patients With Newly Diagnosed Multiple Myeloma (MM) in a Tropical Country-Retrospective Cohort StudyChi Ching Lim, Wai San Wilson Tam, Widanalage Sanjay Prasad De Mel, et al.
Hematology/Oncology and Stem Cell Therapy|April 30, 2018
Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myelomaSanjay de Mel, Yunxin Chen, Adeline Lin, et al.
Critical Reviews in Oncology/Hematology|October 17, 2021
Central nervous system (CNS) prophylaxis in antiCD20-CHOP treated DLBCL at intermediate to high risk for CNS relapse: A systematic review and meta-analysisGuiyi Ho, Cherie Tan, Sanjay de Mel, et al.
Pageof 32